

17-AAG PRODUCT DATA SHEET issue date 01/06/2020

| Product Name: | 17-AAG |
|---|---|
| Product Number: | A061 |
| CAS Number: | 75747-14-7 |
| Molecular Formula: | C ₃₁ H ₄₃ N ₃ O ₈ |
| Molecular Weight: | 585.69 |
| Form: | Powder |
| Appearance: | Purple powder |
| Source: | Synthetic |
| Storage Conditions: | -20 °C |
| Description: | 17-AAG (17-N-Allylamino-17-demethoxygeldanamycin) is a geldanamycin- derived anti-tumor agent currently used in cancer research. It is an inhibitor of heat shock protein 90. |
| | |
| Mechanism of Action: | 17-AAG targets and inactivates Hsp90 (heat shock protein 90), which is expressed in certain types of leukimia and lymphomas as well as solid tumors. |
| Mechanism of Action: Cancer Applications | |
| | expressed in certain types of leukimia and lymphomas as well as solid tumors. 17-AAG has been shown to induce cell-cycle arrest and apoptosis in cultured ALCL cells irrespective of ALK expression. In addition, 17-AAG has shown promising results in the treatment of uveal melanoma through inhibition of |
| Cancer Applications | expressed in certain types of leukimia and lymphomas as well as solid tumors. 17-AAG has been shown to induce cell-cycle arrest and apoptosis in cultured ALCL cells irrespective of ALK expression. In addition, 17-AAG has shown promising results in the treatment of uveal melanoma through inhibition of HSP-90 in tandem with c-Kit inhibition. Hawkins LM, Jayanthan AA, Narendran A (2005) Effects of 17-allylamino-17-demethoxygeldanamycin (17-AAG) on pediatric acute lymphoblastic leukemia (ALL) with respect to Bcr-Abl status and imatinib mesylate sensitivity. Pediatric |

If you need any help, contact us: info@toku-e.com. Find more information on: www.toku-e.com/